Three experts discussed recent notable research of interest to rheumatology professionals across a range of topics.
Secrets & Pearls of Rheumatology at ACR Convergence 2025
Two clinical diagnosticians presented their pearls of wisdom for clinical rheumatologists to take forward when managing patients from the clinics to the hospital wards.
3 AC&R Study Summaries: RA & Frailty, Hydroxychloroquine Can Protect Kidneys in Lupus Nephritis, & PT for Knee OA
Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.
Why Target B Cells in SSc-ILD?
In a recent Arthritis & Rheumatology review article, three experts discuss the use of immunosuppressants to target B cells in a patient with systemic sclerosis-interstitial lung disease.
New Rheumatoid Arthritis Risk Stratification Criteria Released
New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.
As Understanding of Long COVID Deepens, the Search for Therapies Continues
Experts discussed causes of long COVID & potential therapies at this ACR Convergence 2025 session.
Collaboration Is Key to Oral Health in Scleroderma & Sjögren’s Disease
At this ACR Convergence 2025 session, experts discussed the oral manifestations of scleroderma & Sjögren’s disease & the importance of dentists & rheumatologists working together.
The Microbiome’s Impact on Rheumatoid Arthritis & Drug Response
The gut microbiome may trigger RA & predict methotrexate response. ACR Convergence 2025 experts discuss pathogenesis & drug efficacy.
Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus
In this review, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Lupus Nephritis from Bench to Bedside
Urinary biomarkers may have the potential to detect early treatment responses or failures in patients with lupus nephritis, according to Andrea Fava, MD. He and other experts discussed the latest research into lupus nephritis and how apply the recent ACR guideline to refractory cases.